Clinical Trial Update: A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients [Phase 4]

View source ↗

Summary

A Phase 4 randomized, double-blind trial comparing pramipexole at two dosing regimens to placebo in early Parkinson disease completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 4 | Status: COMPLETED | Results posted: 2010-01-13